Results 121 to 130 of about 8,134 (194)

Clinical trial on the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label, single and multiple dosage, parallel group study. [PDF]

Front Pharmacol
Liu H, Liu T, Liu M, Zheng X, Zhong W, Zhao Q, Jiang J, Hu P, Li Y.   +8 more
europepmc   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes. [PDF]

Kidney Int Rep
Catania M, Rivera RF, Kola K, De Rosa LI, Paolisi M, Bianca P, Vezzoli G, Sciarrone Alibrandi MT.   +7 more
europepmc   +1 more source

Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. [PDF]

Eur Heart J Cardiovasc Pharmacother
Cannatà A, Anastasia G, De Marzo V, Caspi O, Bromage D, Porto I, Savarese G, McDonagh T, Cox ZL, Ameri P.   +9 more
europepmc   +1 more source

Hiponatrémia: diagnóstico e tratamento [PDF]

, 2012
Inês Raposo Vieira da Silva
core  

Renal Tubule-Specific Deletion of Nephrocystin 3 <i>(Nphp3)</i> Causes Infantile Nephronophthisis-like Phenotypes in Mice. [PDF]

Int J Mol Sci
Du X, Wang C, Fang Y, Wang G, Zhai Y, Shen Q, Tang X, Xu H.   +7 more
europepmc   +1 more source

Long-Term Tolvaptan Administration in Chinese Patients with Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study in Real Clinical Practice.

Kidney Blood Press Res
Li M, Sun M, Cui S, Liu X, Guo M, Xiao Y, Huang Y, Zhou S, Wang H, Chen X, Li Q.   +10 more
europepmc   +1 more source

Structural insights into antagonist recognition by the vasopressin V2 receptor. [PDF]

Nat Commun
Zhang T, Liu H, You C, Zhang Y, Xu Y, Pan B, Wu C, Jin S, Yin YL, Wu K, Chen Y, Sun H, Si Y, Tan Y, Yin W, Xu HE, Guo D, Jiang Y.   +17 more
europepmc   +1 more source

Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care [PDF]

, 2016
Emmanouil Bagkeris, Helen Carr, Pierre Marc Bouloux, Ploutarchos Tzoulis   +3 more
core   +1 more source

Evolution of Clinical Trial Design in ADPKD. [PDF]

Kidney Int Rep
Roth JR, Dahl NK, Garimella PS.
europepmc   +1 more source

Refining Tolvaptan Dosing in Autosomal Dominant Polycystic Kidney Disease. [PDF]

Kidney360
Dahl NK, Torres VE.
europepmc   +1 more source